Quick Answer
Amphastar Pharmaceuticals, Inc. reported Operating Income Loss of $140.40 million for the year ending 2025.
- Amphastar Pharmaceuticals, Inc. showed a decrease of -31.7% in Operating Income Loss from 2024 to 2025.
- This data is from Amphastar Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: $11.98 million | Q3 2013: $226.0 thousand | Q1 2014: -$1.97 million | Q2 2014: -$1.17 million | Q3 2014: -$7.82 million | Q1 2015: -$7.26 million | Q2 2015: -$10.26 million | Q3 2015: -$3.75 million | Q1 2016: $4.08 million | Q2 2016: $10.33 million | Q3 2016: $5.80 million | Q1 2017: $1.40 million | Q2 2017: $2.19 million | Q3 2017: -$2.94 million | Q1 2018: -$9.78 million | Q2 2018: -$2.94 million | Q3 2018: $2.55 million | Q1 2019: -$3.17 million | Q2 2019: $973.0 thousand | Q3 2019: $2.40 million | Q1 2020: $7.48 million | Q2 2020: -$2.92 million | Q3 2020: $3.52 million | Q1 2021: $10.31 million | Q2 2021: $10.56 million | Q3 2021: $24.77 million | Q1 2022: $21.61 million | Q2 2022: $24.82 million | Q3 2022: $23.23 million | Q1 2023: $33.43 million | Q2 2023: $36.90 million | Q3 2023: $72.68 million | Q1 2024: $48.01 million | Q2 2024: $55.22 million | Q3 2024: $57.05 million | Q1 2025: $37.29 million | Q2 2025: $42.18 million | Q3 2025: $25.32 million.
- Over the full 14 years of available data (2012 to 2025), Amphastar Pharmaceuticals, Inc.'s Operating Income Loss has grown by 452.8%.
- Historical annual values: Fiscal year 2025: $140.40 million | Fiscal year 2024: $205.42 million | Fiscal year 2023: $196.99 million | Fiscal year 2022: $107.50 million | Fiscal year 2021: $69.89 million | Fiscal year 2020: $10.95 million | Fiscal year 2019: -$39.0 thousand | Fiscal year 2018: -$8.62 million | Fiscal year 2017: -$1.27 million | Fiscal year 2016: $15.38 million | Fiscal year 2015: -$6.90 million | Fiscal year 2014: -$17.98 million | Fiscal year 2013: $17.49 million | Fiscal year 2012: $25.40 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: